Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: a pooled analysis from three phase 3 studies

Reinduction with certolizumab pegol in patients with Crohn’s disease experiencing disease exacerbation: 7-year data from the PRECiSE 4 study. 

Safety of long-term treatment with certolizumab pegol in patients with Crohn’s disease, based on a pooled analysis of data from clinical trials. 

Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies

Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus

Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures

Observed incidence rates of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. 

Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy

The first study of certolizumab pegol in combination with methotrexate in DMARD-naïve early rheumatoid arthritis patients led to sustained clinical response and inhibition of radiographic progression at 52 weeks: the C-EARLY randomized, double-blind, controlled phase 3 study. 

Brivaracetam, a selective high affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action